Overview

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
CLN-049-001 is a Phase 1, open-label, multicenter, first-in-human trial of CLN-049 in patients with Relapsed/Refractory AML
Phase:
Phase 1
Details
Lead Sponsor:
Cullinan Oncology, LLC